Palifermin (Kepivance, Biovitrum) is a human recombinant keratinocyte growth factor (KGF) produced in Escherichia coli.
Palifermin costs approximately 5,000 Euros per treatment for a 70 kg patient
When patients with blood cancers undergo high dose chemotherapy and radiation to undergo bone marrow transplant, they usually get severe oral mucositis.
Palifermin binds to epithelial cell-surface receptors and stimulates epithelial cell proliferation,...
more
Palifermin (Kepivance, Biovitrum) is a human recombinant keratinocyte growth factor (KGF) produced in Escherichia coli.
Palifermin costs approximately 5,000 Euros per treatment for a 70 kg patient
When patients with blood cancers undergo high dose chemotherapy and radiation to undergo bone marrow transplant, they usually get severe oral mucositis.
Palifermin binds to epithelial cell-surface receptors and stimulates epithelial cell proliferation, differentiation, and upregulation of cytoprotective mechanisms.
It reduces the incidence and duration of severe oral mucitis by protecting those cells and stimulating the growth of new epithelial cells to build up the mucosal barrier.
less
